We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 9.50 | 9.00 | 10.00 | 9.50 | 9.50 | 9.50 | 613,465 | 07:31:34 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 2.29M | -45.47M | -0.1373 | -0.69 | 31.46M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/12/2023 15:23 | Well, anaemic revenues and disproportionately high cash burn. What could go wrong. At 19p, not many options to raise cash either. | yasx | |
01/12/2023 13:28 | £2.00 you are fortunate ! | toffeeman | |
01/12/2023 10:35 | Lost interest once I heard about GLP-1s. They will ultimately mean there is no demand for what Renalytix offers as there won't be a lot of Kidney disease to worry about. Same for plenty of other weight related ailments. | hpcg | |
01/12/2023 09:52 | please tell me its not going bust. i bought at £2.00 | latifs100 | |
21/11/2023 20:36 | Interesting price action. Makes me wonder about Illumina and Invitae in the US. What exactly is driving these kinds of markets? Illumina and invitae both have good sales but apparent difficulty balancing their books. | f56 | |
21/11/2023 09:35 | I’ve got shot of a large chunk of mine at a huge loss and can’t see any positives for minnow shareholders in the foreseeable future.It appears to be a textbook example of how to fail at marketing and exploiting a great product. My own fault though as there were many opportunities to sell for a nice profit but I got greedy! | jonjoalex | |
21/11/2023 09:02 | Still here! | seadog40 | |
20/11/2023 23:14 | Anyone left here or all sold up and moved on? | jonjoalex | |
14/11/2023 11:20 | "74tom - 15 Mar 2022 - 12:57:11 - 1692 of 2344 Renalytix - AI Solutions Transforming The Management Of Kidney Disease - RENX Idomeneo, your posts remind me of a troll on a football forum pretending to support a team when they actually hate them. What you are saying is akin to going on a Spurs forum and posting that you think Harry Kane will leave on a free transfer or that he's going to retire at 28 to focus on other opportunities. It's complete nonsense to suggest RENX will run out of money, just like it was nonsense to say that raising $50m will double the share count or that shorters are here because they think RENX is like Theranos. Nobody who was invested here would be talking such rubbish, so please quit with the 'we' and go find something else to troll!" This was at £2.50 6 months after the 50 day and the 200 day had rolled over, the company had repeatedly claimed x was going to happen and it subsequently didn't. This guy went on to attack Paul Scott who has been a successful investor analysing several hundred companies a year for over 20 years and has unearthed many multi-baggers over that time. You get the same people who latch onto a stock and attack anybody else with a different view. As an investor you should be interested in looking at all the negatives of your investment, ideally this would be a place where that happens, but it never has. Where somebody would say " you are wrong for these reasons...". NB I didn't mention Theranos because it was a fraud and not relevant here, so he wrongly inferred that. | idomeneo | |
14/11/2023 09:09 | What is the point of this company? Where is the investment thesis? | kemche | |
14/11/2023 07:22 | 1000 tests done, $2.8m on 'research' ! :) Earnings $0.5m and the cost for doing those tests? $8.8m. This company is managed by people who have never had a maths lesson in their lives. Either that or this was always meant to be a cash/retirement cow to reward Mt Sinai researchers. It's bankrupt - you cannot plan when you have three months money left and your revenue is 6% of your costs. | faz | |
13/11/2023 15:46 | $25m in June running 80? staff at $10m pq would leave $15m at 30 Sep & $10m on 15 Nov so runway till 15 Feb unless there is delivery on any of the possible catalysts. On the other hand detail of catalysts has been based on what directors have said. The track record of what they have said to expect has been unreliable on catalysts and misleading in terms of test volumes. How on earth is the army employed? It seems as though it is kept marching firmly on for the future without regard for the timing of commerciality. There must be a Plan B to reach commerciality or they would stop building. It seems too easy to imagine an RNS announcing a delisting as the market no longer values the opportunity highly enough and a deeper pool of capital is available delisted. If not why do directors seem secure still having got through the capital raised by their promises? It does seem too much to hope that they will actually deliver enough from their predictions this time to stave off huge dilution or costs have been sufficiently trimmed to match the pace of uptake in the market or volumes have grown to properly raise trend assumptions. Grim | red171 | |
07/11/2023 15:56 | At the moment cash is king…..this company could run out of cash and cease to exist…. Against that view it has an approved product which should generate value for health systems and patient benefit….it will likely survive but current shareholders may not gain as much as they expected because of expected dilution. Shagga’s £2 has a lot of hope embedded in the price. | 1jat | |
06/11/2023 17:01 | People bought in the past due to covid and biotech companies, they did ok out of it. the charts says it all !. THis should be good for £2 per share so undervalued imho | sirshagalot | |
06/11/2023 09:14 | From £12 to 40p in a couple of years. It’s clearly been a hostile market for biotech but that is an extraordinary decline. Let’s hope there is sufficient funding available to weather the storm and have some kind of recovery next year. | jonjoalex | |
06/11/2023 09:03 | No reflection here on the main story for investors, i.e. how could a market cap of nearly £1bn in May 2021, slip away to almost nothing now, with no comment on the phenomenon Here is what a typical shareholder here was thinking: wan22 Apr '21 - 06:28 - 1017 of 2336 Excellent news today, big in itself, as exemplified by the formation of a market access team focused on contracting with VA, DoD, and IHS facilities. It's only part of the initial stage of commercialisation, but wow, what a start! Not to mention the recognition and kudos in securing such an important contract. Very well done to the Renalytix team! | ydderf | |
05/11/2023 11:43 | Looks like even the die hards have abandoned this pos. Very sad to see such a savage decline in the share price | jonjoalex | |
20/10/2023 10:21 | Managed to buy another 10k at 46.75p. Shown as a sell. Level 2 looking positive. | videologic | |
09/10/2023 17:46 | Took the opportunity to sell some of my other shares in my Isa holdings to take another 21,000+ today. Good price. Very happy. | videologic | |
06/10/2023 18:10 | Dilution death spiral unfortunately | bertiebingo | |
06/10/2023 13:09 | This is a worse reaction than usual! Good news accompanied by fall to new all-time low. What is going on?? | seadog40 | |
05/10/2023 11:41 | so many stocks just collapsing to nothing. when will there be a bull market again? | purple11 | |
03/10/2023 11:40 | Cashburn similar to past. Cap raise delayed due to technical issues. As shares fall the cap raise becomes more dilutive as shares fall... so they fall more.No reason for shares to rise until these issues are solved unfortunately. | bertiebingo | |
03/10/2023 09:45 | Guess they don't know why price has fallen back so much after a run of good news. Plus they mentioned international potential too. | babbler |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions